Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The probucol angioplasty restenosis trial

Journal of the American College of Cardiology

Volumn 30, Issue 4, 1997, Pages 855-862

  Yokoi, Hisashi ^a   Daida, Hiroyuki ^a,k   Kuwabara, Yoichi ^b   Nishikawa, Hideo ^c   Takatsu, Fumimaro ^d   Tomihara, Hitoshi ^e   Nakata, Yasuro ^e   Kutsumi, Yasunori ^f   Ohshima, Shigeru ^g   Nishiyama, Shinichiro ^h   Seki, Akira ^h   Kato, Kenichi ⁱ   Nishimura, Shigeyuki ⁱ   Kanoh, Tatsuji ^j   Yamaguchi, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c ISE RED CROSS HOSPITAL   (Japan)

^d ANJO KOSEI HOSPITAL   (Japan)

^e JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^f UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^g Gunma Cancer Center   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ YOKOHAMA ROSAI HOSPITAL   (Japan)

^j JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^k JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; PROBUCOL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FOLLOW UP; HUMAN; INTERVENTIONAL RADIOLOGY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; PROBUCOL; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 0030768434     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00270-2     Document Type: Article

References (41)

1. Holmes DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty: a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77C-81C.
2. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-71.
3. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 299 patients. J Am Coll Cardiol 1988;12:616-23.
4. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-7.
5. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;2:362-9.
6. Leaf A, Jorgrnsen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.
7. Pepin CJ, Hirshfeld JW, Macdonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990;81:1753-61.
8. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
9. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
10. Gey FK, Puska P, Jourdon P, et al. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross cultural epidemiology. Am J Clin Nutr 1991;53:326-34.
11. Stampfer MJ, Hennekins CH, Manson JE, et al. Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med 1993;328: 1444-9.
12. Rimm EB, Stampfer MJ, Ascheris A, et al. Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993;328:1450-6.
13. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84: 5928-31.
14. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in mactophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
15. Wilson RB, Middleton CC, Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis off rabbits. J Nutr 1978;108: 1858-67.
16. Boscoboinik D, Szewczyk A, Hensey C, et al. Inhibition of cell proliferation by alpha-tocopherol: role of protein kinase C. J Biol Chem 1991;266:6188-94.
17. Ozer Nk, Pallozza P, Boscoboinik D, Azzi A. D-Alpha-tocopherol inhibits low density lipoprotein-induced proliferation and protein kinase C activity in vascular smooth muscle cells. FEBS Lett 1993;322:307-10.
18. Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery ballon injury: a possible role for antioxidant in restenosis. Circulation 1993;88:628-37.
19. Freyschuss A, Stiko-Rahm A, Awedenborg J, et al. Antioxidant treatment inhibits the development of intimai thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993;91:1282-8.
20. Godfried SL, Deckelbaum LI. Natural antioxidants and restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1995;129:203-10.
21. Parthasathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-4.
22. Lee YJ, Daida H, Yokoi H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996;37:327-32.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
24. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single vessel disease. Circulation 1986;73:710-7.
25. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-45.
26. DeMaio SJ, King SB, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992;11:68-73.
27. Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993;15:374-82.
28. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effect of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-9.
29. Tardif JC, Cote G, Lesperance J, et al. Prevention of restenosis by pre- and post-PTCA probucol therapy: a randomized clinical trial [abstract]. Circulation 1996;94 suppl I:I-91.
30. Wilcox JN. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol 1993;72:88E-95E.
31. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70:593-9.
32. Ku G, Doherty NS, Wolos JA, Jackson LR. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. Am J Cardiol 1988;62:77B-81B.
33. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-8.
34. Stiko-Rahm A, Hultgardh-Nilsson A, Regnestöm J, Regnstrom J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 1992;12:1099-109.
35. Gwynne JT. Probucol, high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol 1988;62:48B-51B.
36. Bridges AB, Scott NA, Belch JJF. Probucol, a superoxide free radical scavenger in vitro. Atherosclerosis 1991;89:263-5.
37. Ku G, Doherty NS, Schmidt LF, Jackson RL, Dinerstein RJ. Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties. FASEB J 1990;4:1645-53.
38. Akeron AL, Woods CW, Mosher LB, Thomas CE, Jackson RL. Inhibition of IL-1-β expression in THP-1 cells by probucol and tocopherol. Atherosclerosis 1991;86:261-70.
39. Chang MY, Sasahara M, Chait A, Raines EW, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol: cellular composition and proliferation. Arterioscler Thromb Vase Biol 1995;15:1631-40.
40. Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB, King SB III. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Biol 1995;15:156-65.
41. Reaven PD, Parthasarathy S, Beltz WF, Wiztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318-24.